Related Experiment Videos
Graft-versus-host disease: host and donor views
1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98104.
Seminars in Hematology
|October 1, 1993
Summary
Graft-versus-host disease (GVHD) is a major transplantation barrier involving T-cell activation and cytokine release. Understanding these mechanisms is key to preventing GVHD and improving transplant outcomes.
Area of Science:
- Immunology
- Transplantation Biology
Background:
- Major histocompatibility complex (MHC) antigens, known as HLA in humans, are primary barriers in transplantation.
- Graft-versus-host disease (GVHD) can occur following marrow, solid organ transplantation, or blood product transfusion.
Purpose of the Study:
- To elucidate the immunological mechanisms underlying GVHD.
- To explore the role of T-cell activation, cytokines, and effector cells in GVHD pathogenesis.
Main Methods:
- The study reviews the recognition of antigen-presenting cells by T lymphocytes via T-cell receptors and accessory molecules (CD4, CD8).
- It examines T-cell activation, interleukin-2 receptor (IL-2R) expression, IL-2 production, and subsequent clonal proliferation and differentiation.
- The role of various cytokines (e.g., interferon-gamma, TNF-alpha, IL-2-9, GM-CSF) and effector cells (cytotoxic T cells, NK cells, macrophages) is discussed.
Main Results:
- T-cell activation leads to the secretion of numerous cytokines that contribute to cell and tissue death.
- Cytokines can alter vascular endothelium, potentially affecting cell homing and allogeneic interactions.
- GVHD prophylaxis and exogenous growth factors/cytokines may modulate immune responses, with observed adverse reactions to IL-2 and interferon, and potential benefits from soluble IL-1R antagonists.
Conclusions:
- GVHD involves a complex interplay of immune cells and cytokines, presenting a significant challenge in transplantation.
- Further research into modulating these pathways, including the use of cytokine antagonists, may offer therapeutic strategies to mitigate GVHD while preserving beneficial immune responses.